Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Gamma-PN3 in Healthy Adults
NCT05667740Phase 1Completed
- Sponsor
- GPN Vaccines
- Start
- Jan 2023
- Primary completion
- Oct 2023
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gamma-pn3 in pneumococcal infection (4 arms), sponsored by GPN Vaccines. Primary endpoints: Adverse events and clinical laboratory measures at 57 days and Immunogenicity at 57 days. Started Jan 2023; status: completed.
02
Drugs
gamma-pn3
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT05667740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667740.